After holding several virtual editions due to the pandemic, Barcelona hosted the meeting of the International Neuropsychological Society between 6th and 8th July, an event that brought together scientific knowledge and practical application with the aim of developing science and implementing new and better solutions for people.
Ace Alzheimer Center Barcelona had a prominent presence with the presentation of the results of the administration of Facememory®, the tool for early detection of cognitive impairment, administered in our BIOFACE cohort whose is made up of people with mild cognitive impairment and under 65 years of age.
Dr. Montse Alegret, head of neuropsychology at Ace, attended this edition in which she highlighted “the return to normality of the INS meetings and the high quality of the scientific presentations. It must be recognized that these meetings are more fruitful in face-to-face format, since the exchange of ideas and opinions is much easier face to face, as well as the creation of synergies that can benefit our future projects”.
Facememory® is the first verbal episodic memory test self-administered through a Tablet with voice recognition and touch screen and with automatic scoring subsequently reviewed by Ace's team of neuropsychologists.
Its purpose is to discriminate between cognitively healthy and cognitive impairment. For this, the study that was presented at the INS meeting analysed the score obtained in the tests administered in the BIOFACE cohort of Ace, obtaining as main conclusions that:
1. Facememory® is a promising tool for the detection of memory deficits due to Alzheimer's disease, but also due to other aetiologies.
2. It is an opportunity to facilitate early detection of cognitive impairment.
3. In science, it is an excellent screening test tool for enrolling people in clinical trials.
